Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(5.02) per share. This is a 71.28 percent increase over losses of $(17.48) per share from the same period last year.
Related Posts
Needham Reiterates Buy on Sage Therapeutics, Maintains $70 Price Target
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Buy and maintains $70 price target.
InnovAge Holding’s Earnings Outlook
InnovAge Holding (NASDAQ:INNV) is set to give its latest quarterly earnings report on Tuesday, 2022-09-13. Here's what investors need to know before the announcement.
Analysts estimate that InnovAge Holding will report an earnings per share (EPS) of $-0.03.
Farmmi Shares Gain On 31% Revenue Growth In H1’21
Agriculture products supplier Farmmi Inc (NASDAQ:FAMI) reported the first-half FY21 sales growth of 31% year-on-year, to $17.79 million. The increased sales volume…